Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CD137 agonist

DRUG CLASS:

CD137 agonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3
HER-2 positive	Biliary Tract Cancer	HER-2 positive	Biliary Tract Cancer	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3
HER-2 positive	Urothelial Cancer	HER-2 positive	Urothelial Cancer	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3
CD20 positive	Non-Hodgkin’s Lymphoma	CD20 positive	Non-Hodgkin’s Lymphoma	rituximab + PF-05082566 Sensitive: C3 – Early Trials rituximab + PF-05082566 Sensitive : C3	rituximab + PF-05082566 Sensitive: C3 – Early Trials rituximab + PF-05082566 Sensitive : C3
CLDN18.2 expression	Gastroesophageal Cancer	CLDN18.2 expression	Gastroesophageal Cancer	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3
HER-2 positive	Pancreatic Cancer	HER-2 positive	Pancreatic Cancer	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4
HER-2 positive	Melanoma	HER-2 positive	Melanoma	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	PM1003 Sensitive: C4 – Case Studies PM1003 Sensitive : C4	PM1003 Sensitive: C4 – Case Studies PM1003 Sensitive : C4
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	ABL105 Sensitive: D – Preclinical ABL105 Sensitive : D	ABL105 Sensitive: D – Preclinical ABL105 Sensitive : D